At present, methods, components and packages for the treatment of timidity or tumor disorders are provided, including: Vera type polypeptide, primary gallbladder fibrosis, thrombosis and basic thrombosis. Claim 1: a method for the treatment of highly diffusive disorders, including the effective treatment of patients with JAK inhibitors and the effective treatment of PI3K inhibitors. JAK inhibitors were selected from a group consisting of ruxotinib, fedratinib, tofacitinib, baritinib, estaurtinib, pacitinib, deirnotinib, xl019, azd1480, incb039110, ly2784544,BMS911543 NS018 GLPG0634 GLPG0788 o N- (cianometil) -4- 2- (4-morfolinoanilino) pirimidin-4-iI benzamida o sus sales farmac uticamente aceptables Reivindicaci n 3 El m todo de cualquiera de las reivindicaciones 1 - 2 donde el inhibidor de WX-037, AEZS-129, PA799, ZSTK474, AS252424, TGX221, TG100115, IC87114, (S) -2- (1 - ((9H-purin-6-iI) amino) propyl) -5-fluorine-3- phenylquinazolin-4 (3H) -one, (S) -2- (1 - ((9H-purin-6-yl) amino) ethyl) -6-fluoro-3-phenylquinazolin-4 (3H) -one, (S ) -2,4-diamino-6 - (((5-chloro-8-fluoro-4-oxo-3- (pyridin-3-yl) -3,4-dihydroquinazolin-2-yl) (cyclopropyl) methyl) amino) pyrimidine-5-carbonitrile, (S) -3- (1 - ((9H-purin-6-yl) amino) ethyl) -8-chloro-2-phenylisoquinolin-1 (2H) -one, (S) -2,4-diamino-6- (cyclopropyl (5,8-dichloro-4-oxo-3- (pyridin-3-yl) -3,4-dihydroquinazolin-2-yl) methylamino) pyrimidine-5-carbonitrile, (S) -2,4-diamino-6- (1- (5-chloro-3- (4-methypyridin-3-iI) -4-oxo-3,4-dihydroquinazolin-2-yl) ethylamino) pyrimidine- 5-carbonitrile,(S) - Di Di Di Di Di Di Di Di Di Di Di Di Di Di Di Di Di Di 1 - (5-chloro-3 - (5-fluoroopidin-3-il) - 4-oxo-3, Two two two two two two two two two two two two two two two two two two two two two two two two two two two two two two two two two two two two two two two two two two two two two five carbonate,(S) -2,4-diamino-6 - ((5-chloro-3- (5-fluoropyridin-3-yl) -4-oxo-3,4-dihydroquinazolin-2-yl) (cyclopropyl) methylamino) pyrimidine -
